57.51

0.37% 0.2369

Ani Pharmaceuticals Inc (ANIP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ani Pharmaceuticals Inc stock is traded at $57.51, with a volume of 105.27K. It is up +0.37% in the last 24 hours and down -15.93% over the past month. ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Previous Close:

$57.27

Open:

$56.96

24h Volume:

105.27K

Relative Volume:

0.27

Market Cap:

$1.24B

Revenue:

$486.82M

Net Income/Loss:

$18.78M

P/E Ratio:

70.13

EPS:

0.82

Net Cash Flow:

$100.45M

1W Performance:

-4.18%

1M Performance:

-15.93%

6M Performance:

+1.00%

1Y Performance:

-4.77%

1-Day Range:

$56.71

$57.79

1-Week Range:

$56.71

$61.23

52-Week Range:

$52.50

$77.00

Ani Pharmaceuticals Inc Stock (ANIP) Company Profile

Name

Ani Pharmaceuticals Inc

Sector

Healthcare (1178)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

(218) 634-3500

Address

210 MAIN STREET WEST, BAUDETTE, MN

Employee

897

Twitter

Next Earnings Date

2024-12-08

Latest SEC Filings

ANIP's Discussions on Twitter

Compare ANIP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIP Ani Pharmaceuticals Inc	57.42	1.29B	486.82M	18.78M	100.45M	0.82
HLN Haleon Plc Adr	11.17	48.05B	14.35B	1.85B	0	0.4023
ZTS Zoetis Inc	162.15	71.39B	9.29B	2.52B	2.28B	5.57
RDHL Redhill Biopharma Ltd Adr	1.84	3.20M	35.75M	11.57M	-26.25M	-3.8069
TAK Takeda Pharmaceutical Co Adr	14.53	43.73B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.91	19.35B	16.54B	-1.64B	749.00M	-1.45

Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-14-25	Initiated	Jefferies	Buy
Mar-12-25	Initiated	JP Morgan	Overweight
Dec-11-24	Initiated	Leerink Partners	Outperform
Oct-11-24	Initiated	Piper Sandler	Overweight
Mar-15-24	Initiated	CapitalOne	Overweight
Aug-22-23	Reiterated	H.C. Wainwright	Buy
Mar-01-23	Initiated	Guggenheim	Buy
Sep-07-22	Initiated	H.C. Wainwright	Buy
Nov-02-21	Initiated	Truist	Buy
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform
Oct-16-17	Reiterated	Canaccord Genuity	Buy
Jul-31-17	Initiated	Canaccord Genuity	Buy
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy
Aug-05-15	Reiterated	Oppenheimer	Outperform
Aug-04-15	Reiterated	ROTH Capital	Neutral
Jul-31-15	Reiterated	Oppenheimer	Outperform
Jul-15-15	Reiterated	ROTH Capital	Neutral
Jun-23-15	Reiterated	Oppenheimer	Outperform
May-18-15	Reiterated	ROTH Capital	Neutral
May-06-15	Reiterated	Oppenheimer	Outperform
Apr-10-15	Downgrade	ROTH Capital	Buy → Neutral
Feb-26-15	Reiterated	ROTH Capital	Buy
Feb-18-15	Reiterated	Oppenheimer	Outperform

View All

Ani Pharmaceuticals Inc Stock (ANIP) Latest News

07:31 AM

ANI Pharmaceuticals Launches Phase 4 Trial of Cortrophin Gel for Acute Gout Flares - marketscreener.com

May 22, 2025

ANI Pharmaceuticals (ANIP) Starts Phase 4 Trial for Acute Gout Treatment | ANIP Stock News - GuruFocus

May 22, 2025

ANI Pharmaceuticals Announces Initiation of Phase 4 - GlobeNewswire

May 22, 2025

May 21, 2025

ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth - insights.citeline.com

May 21, 2025

May 20, 2025

ANI Pharmaceuticals To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq

May 20, 2025

May 16, 2025

We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation - simplywall.st

May 16, 2025

May 13, 2025

Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Voyager Therapeutics (VYGR) and Privia Health Group (PRVA) - The Globe and Mail

May 13, 2025

May 12, 2025

ANI Pharmaceuticals (ANIP) Price Target Raised by Raymond James - GuruFocus

May 12, 2025

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ - GlobeNewswire

May 12, 2025

ANI Pharmaceuticals (ANIP) Receives Buy Rating from Guggenheim | - GuruFocus

May 12, 2025

ANI Pharmaceuticals (ANIP) Receives Buy Rating from Guggenheim | ANIP Stock News - GuruFocus

May 12, 2025

May 10, 2025

ANI Pharmaceuticals raises 2025 revenue guidance to $768M-$793M with 25%-29% growth - MSN

May 10, 2025

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

Earnings call transcript: ANI Pharmaceuticals beats Q1 2025 forecasts, stock surges - Investing.com UK

May 10, 2025